ArticleFrontiers in cellular neuroscience2014
Modulation of subventricular zone oligodendrogenesis: a role for hemopressin?
Article in Frontiers in cellular neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Extracellular Matrix Proteins Differentiate Postnatal Mouse Retina Neurospheres into Neurons or Glia Profiles.Neurochemical research · 2025Article
- (m) RVD-hemopressin (α) Ameliorated Oxidative Stress, Apoptosis and Damage to the BDNF/TrkB/Akt Pathway Induced by Scopolamine in HT22 Cells.Neurotoxicity research · 2023Article
- Activation of cannabinoid type 1 receptor (CB1) modulates oligodendroglial process branching complexity in rat hippocampal cultures stimulated by olfactory ensheathing glia-conditioned medium.Frontiers in cellular neuroscience · 2023Article
- Role of integrating cannabinoids and the endocannabinoid system in neonatal hypoxic-ischaemic encephalopathy.Frontiers in molecular neuroscience · 2023Review
- Article
- Hemopressin as a breakthrough for the cannabinoid field.Neuropharmacology · 2021Review
- Quality of Life and a Surveillant Endocannabinoid System.Frontiers in neuroscience · 2021Review
- Cell Calcium Imaging as a Reliable Method to Study Neuron-Glial Circuits.Frontiers in neuroscience · 2020Review
- New Insights Into Peptide Cannabinoids: Structure, Biosynthesis and Signaling.Frontiers in pharmacology · 2020Review
- Intracellular Peptides in Cell Biology and Pharmacology.Biomolecules · 2019Review
- The role of cannabinoids in adult neurogenesis.British journal of pharmacology · 2015Review
- Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies.Nature reviews. Neuroscience · 2014Review
- The ventricular-subventricular zone: a source of oligodendrocytes in the adult brain.Frontiers in cellular neuroscience · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neural stem cells (NSCs) from the subventricular zone (SVZ) have been indicated as a source of new oligodendrocytes to use in regenerative medicine for myelin pathologies. Indeed, NSCs are multipotent cells that can self-renew and differentiate into all neural cell types of the central nervous system. In normal conditions, SVZ cells are poorly oligodendrogenic, nevertheless their oligodendrogenic potential is boosted following demyelination. Importantly, progressive restriction into the oligodendrocyte fate is specified by extrinsic and intrinsic factors, endocannabinoids being one of these factors. Although a role for endocannabinoids in oligodendrogenesis has already been foreseen, selective agonists and antagonists of cannabinoids receptors produce severe adverse side effects. Herein, we show that hemopressin (Hp), a modulator of CB1 receptors, increased oligodendroglial differentiation in SVZ neural stem/progenitor cell cultures derived from neonatal mice. The original results presented in this work suggest that Hp and derivates may be of potential interest for the development of future strategies to treat demyelinating diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.